OCR is specialized in the design of clinical studies of pets with naturally occurring pathologies
for efficacy assessment of drug candidates and medical devices for Human Health.
OCR and ImaBiotech initiate a strategic partnership to provide in situ drug efficacy and target exposure services in Pets with naturally occuring tumors.
OCR and Biofortis discuss the importance of the microbiome, especially in the field of oncology, in an interview with Dr Tierny and Dr Rybicka.
OCR together with ImmunXperts and Rarecells win k€520 funding in Eureka Eurostars program to initiate €1,3m “ICOM” platform for preclinical and clinical human cancer drug evaluation in pet dog’s model.
OCR the company revolutionising the selection of effective drug candidates for cancer, raises €1.25m from Newfund, NFA and the management team in order to accelerate its growth.
OCR emerges as a leading vet CRO in Europe after signing a succession of major contracts.
OCR and Pierre Fabre’s Phase I Clinical Pharmacology Study published in prestigious Clinical Cancer Research journal.
OCR represented at 106th AACR Annual Meeting by Dr. Grégoire Prevost.
OCR and Ecrins Therapeutics initiate €1.9m “Dog to Man” pioneering translational research programme to advance human and vet oncology treatment.
OCR and PRISM announce ground-breaking research collaboration to advance real-time diagnosis using mass spectrometry.
OCR strengthens veterinary and R&D expertise to respond to the needs of the pharmaceutical industry.
Stay connected to OCR,
subscribe to our Newsletter !
Surname - Name *
Email address *
I’m a vet
I’m a laboratory
WE WOULD BE DELIGHTED TO HEAR FROM YOU !
Parc Eurasanté – Lille Métropole
80 rue du Dr Yersin, 59120 Loos